Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations
    • ORGAN PROCUREMENT AND TRANSPLANTATION—M.D. Fla.: CMS organ procurement ranking rule survives APA challenge
    • AUDITS AND MONITORING—OIG REPORTS: Tennessee Medicaid claimed $59.3 million in improper Medicaid reimbursement for targeted case management services
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • CONTROLLED SUBSTANCES—NOTICES: DEA denies cannabis manufacturer registration bid over compliance gaps
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • COSMETICS—N.D. Cal.: Lip balm false labeling suit moves forward
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • DRUGS AND BIOLOGICS—NOTICES: FDA clears path for generic ISTURISA approvals
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • MEDICAL DEVICES—FINAL RULES: FDA establishes Class II controls for vascular autograft storage solutions
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • PRESCRIPTION DRUGS—OIG REPORTS: CMS policy on Part B drug price-substitutions saved Medicare and enrollees $1.6 million in 2024
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • QUALITY OF CARE—D.D.C.: Jurisdictional nuances lead to stalemate on dispositive motions about HHS NPDB malpractice report decision
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • SENATE NEWS—Bipartisan Bill to Update HIPAA Cyber Rules Clears Senate
      • You have 1 more complimentary views available this month. Log in if you are already a customer
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations

    Health Law Daily Wrap Up, DRUGS AND BIOLOGICS—NOTICES: FDA clears path for generic ISTURISA approvals, (Oct 2, 2026)

    By WK Editorial Staff

    FDA's determination preserves a pathway for generic competition by allowing abbreviated new drug applications referencing osilodrostat tablets to remain eligible for approval, provided all other regulatory requirements are met.

    The FDA determined that ...

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use